Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy

Iacopo Olivotto1, Roberto Gistri, Pasquale Petrone

  • 1Cardiologia S. Luca, Azienda Ospedaliera Careggi, Florence, Italy. iacopo.olivotto@virgilio.it

Insights

Maximum left ventricular wall thickness did not predict sudden death or cardiovascular mortality in hypertrophic cardiomyopathy (HCM) patients over 12 years. Extreme thickness may indicate risk only in very young patients, underscoring a multifactorial risk approach.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Clinical Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart disease.
  • Previous studies suggested a link between maximum left ventricular (LV) wall thickness and sudden cardiac death risk in HCM.
  • This association requires further investigation for accurate risk stratification and treatment strategies.

Purpose of the Study:

  • To evaluate the relationship between maximum left ventricular (LV) wall thickness and patient outcomes in hypertrophic cardiomyopathy (HCM).
  • To determine if LV wall thickness is an independent predictor of sudden death or overall cardiovascular mortality in HCM.
  • To inform risk stratification protocols for HCM patients.

Main Methods:

  • A cohort of 237 hypertrophic cardiomyopathy (HCM) patients was analyzed.
  • Patients were categorized into five groups based on echocardiographically measured maximum LV wall thickness.
  • Mortality and risk profiles were assessed over a mean follow-up period of 12 years.

Main Results:

  • No significant association was found between maximum LV wall thickness and the risk of sudden death (p = 0.37) or overall cardiovascular mortality (p = 0.7).
  • Mortality rates were similar across thickness groups, except for those with LV thickness ≤15 mm, who had a benign course.
  • Extreme LV thickness (> or =30 mm) showed a potential risk marker only in patients diagnosed at <18 years of age.

Conclusions:

  • Maximum LV wall thickness is not independently associated with cardiovascular mortality in a general HCM population over 12 years.
  • Risk stratification in HCM should incorporate a multifactorial approach, considering LV thickness alongside other clinical factors.
  • Extreme LV wall thickness may be a risk marker for sudden death in very young individuals diagnosed with HCM.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...